Positive Association Between Location of Melanoma, Ultraviolet Signature, Tumor Mutational Burden, and Response to Anti–PD-1 TherapyL. Dousset, Lise Boussemart, F. Poizeau et al.|JCO Precision Oncology|2021Cited by 61
Update of survival and cost of metastatic melanoma with new drugs: Estimations from the MelBase cohortM. Kandel, Isabelle Borget, Laurent Mortier et al.|European Journal of Cancer|2018Cited by 38
Relevance of body mass index as a predictor of systemic therapy outcomes in metastatic melanoma: analysis of the MelBase French cohort data☆Y. Di Filippo, Henri Montaudié, Stéphane Dalle et al.|Annals of Oncology|2020Cited by 30
Quality‐of‐life assessment in French patients with metastatic melanoma in real lifeM. Kandel, Isabelle Borget, Stéphane Dalle et al.|Cancer|2019Cited by 14
When to stop immunotherapy for advanced melanoma: the emulated target trialsMathilde Amiot, Raphaël Porcher, Laurent Mortier et al.|EClinicalMedicine|2024Cited by 7